Publicacións en colaboración con investigadores/as de Centro de Investigación Biomédica de La Rioja (12)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

    Frontiers in Cellular and Infection Microbiology, Vol. 13

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Igf1r as a potential pharmacological target in allergic asthma

    Biomedicines, Vol. 9, Núm. 8

  2. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

    Nature, Vol. 595, Núm. 7869, pp. 707-712

  3. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant

    Nature Genetics, Vol. 53, Núm. 10, pp. 1405-1414

2020

  1. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  2. Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 1, pp. 28-32

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

2017

  1. SEOM–SERAM–SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico., pp. 1-16

2014

  1. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: Comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen

    HIV Medicine, Vol. 15, Núm. 9, pp. 547-556